Advertisement
Research Article| Volume 31, ISSUE 11, P3004-3015, October 28, 2021

Download started.

Ok

Quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for type 2 diabetes mellitus: A systematic review

      Highlights

      • Complementary and alternative medicine (CAM) use is prevalent among patients with type 2 diabetes mellitus (T2DM)
      • An assessment of CAM recommendations in T2DM practice guidelines is absent
      • CAM recommendations were present in one quarter of all eligible guidelines
      • The quality of CAM recommendations varied within and across guidelines
      • A gap exists as the majority of guidelines do not provide CAM recommendations

      Abstract

      Aims

      Approximately 70% of Americans with diabetes have used complementary and alternative medicine (CAM) in the past year. Healthcare providers often receive minimal training on these therapies and subsequently rely on clinical practice guidelines (CPGs) to supplement their knowledge about the safe and effective use of CAM for the treatment/management of type 2 diabetes mellitus (T2DM). The purpose of this systematic review is to determine the quantity and assess the quality of CAM recommendations in CPGs for the treatment and/or management of T2DM.

      Data synthesis

      MEDLINE, EMBASE, and CINAHL were systematically searched from 2009 to 2020, in addition to the Guidelines International Network and the National Center for Complementary and Integrative Health websites. CPGs containing treatment and/or management recommendations for T2DM were eligible; those with CAM recommendations were quality-assessed with the AGREE II instrument twice, once for the overall CPG and once for the CAM sections. Twenty-seven CPGs were deemed eligible, of which 7 made CAM recommendations. Mean scaled domain percentages were (overall, CAM): scope and purpose (89.7%, 79.8%), clarity of presentation (85.7%, 48.4%), stakeholder involvement (67.9%, 28.2%), applicability (54.8%, 20.2%), rigour of development (49.7%, 35.7%), and editorial independence (44.1%, 44.1%).

      Conclusions

      Quality varied within and across CPGs; domain scores across CAM sections generally scored lower than the overall CPG. Given that CAM therapies for T2DM are only represented in one-quarter of eligible CPGs and are of lower quality, a knowledge gap exists for healthcare providers who seek evidence-based information on this topic in order to effectively counsel inquiring patients.

      Keywords

      Abbreviations:

      AGREE II (Appraisal of Guidelines for Research & Evaluation II), CAM (complementary and alternative medicine), CPG (clinical practice guideline), DHS (dietary and herbal supplement), PICO (Population, Intervention, Comparison and Outcome), PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), TCM (traditional Chinese medicine)

      Background

      Diabetes is a condition that currently affects more than 100 million adults in the United States [
      New CDC report: more than 100 million Americans have diabetes or prediabetes | CDC Online Newsroom. Centers for Disease Control and Prevention.
      ]. The most common is type 2 which affects around 90% of individuals with diabetes []. This type develops in adulthood and arises when the pancreas produces insulin adequately but the body is unable to transport glucose into the cells for fuel [,
      • Association A.D.
      Diagnosis and classification of diabetes mellitus.
      ]. The study of diabetes is important since high blood sugar can result in kidney disease, retinopathy that may cause blindness, diabetic peripheral neuropathy from nerve damage, and increased risk of foot ulcers, among other complications [,
      • Association A.D.
      Diagnosis and classification of diabetes mellitus.
      ]. Type 2 diabetes mellitus (T2DM) can be managed through medications, such as alpha-glucosidase inhibitors, biguanides, SGLT2 inhibitors, and insulin, as well as through controlled diet and exercise [,
      • Upadhyay J.
      • Polyzos S.A.
      • Perakakis N.
      • Thakkar B.
      • Paschou S.A.
      • Katsiki N.
      • et al.
      Pharmacotherapy of type 2 diabetes: an update.
      ]. The use of complementary and alternative medicine (CAM) therapies is also prevalent among T2DM patients. A national survey revealed that 72.8% of Americans with diabetes used CAM in the past year [
      • Bell R.A.
      • Suerken C.K.
      • Grzywacz J.G.
      • Lang W.
      • et al.
      Complementary and alternative medicine use among adults with diabetes in the United States.
      ]. CAM encompasses a wide variety of therapies that are not a part of conventional medicine. Specifically, “complementary medicine” refers to a non-mainstream practice used together with conventional medicine, while “alternative medicine” refers to those used in place of conventional medicine [
      Complementary, alternative, or integrative health: what's in a name?. NCCIH.
      ,
      • Ng J.Y.
      • Boon H.S.
      • Thompson A.K.
      • Whitehead C.R.
      Making sense of “alternative”, “complementary”, “unconventional” and “integrative” medicine: exploring the terms and meanings through a textual analysis.
      ].
      Examples of common CAM therapies used for T2DM include dietary and herbal supplements (DHS), yoga, traditional Chinese medicine (TCM), and manual therapies [
      Complementary and alternative medicine for diabetes. Diabetes Canada.
      ]. Some specific DHSs include chromium, which has been suggested to improve glycemic control in T2DM [
      • Asbaghi O.
      • Fatemeh N.
      • Mahnaz R.K.
      • Ehsan G.
      • Elham E.
      • Behzad N.
      • et al.
      Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
      ], and aloe vera which has been shown to lower glycated haemoglobin (A1C) by at least 0.5% in individuals with T2DM [
      • Dick W.R.
      • Fletcher E.A.
      • Shah S.A.
      Reduction of fasting blood glucose and hemoglobin A1c using oral aloe vera: a meta-analysis.
      ]. Yoga, a spiritual practice involving breathing, meditation, and postures has shown to have a positive effect on glycemic control and lipid levels [
      Complementary and alternative medicine for diabetes. Diabetes Canada.
      ,
      • Innes K.E.
      • Selfe T.K.
      Yoga for adults with type 2 diabetes: a systematic review of controlled trials.
      ]. One commonly used TCM for diabetes is acupuncture, which is used to relieve pain resulting from nerve damage [
      Complementary and alternative medicine for diabetes. Diabetes Canada.
      ,
      Complementary and alternative medicine for diabetes - health Encyclopedia. University of Rochester Medical Center.
      ]. Individuals with diabetes also seek manual therapies including chiropractic, physiotherapy, shiatsu, and massage therapy to help with musculoskeletal issues [
      Complementary and alternative medicine for diabetes. Diabetes Canada.
      ]. Despite the high prevalence of CAM use among T2DM patients, many healthcare providers still report being unfamiliar with and uncomfortable counselling patients about these therapies [
      • Wahner-Roedler D.L.
      • Lee M.C.
      • Chon T.Y.
      • Cha S.S.
      • Loehrer L.L.
      • Bauer B.A.
      Physicians' attitudes toward complementary and alternative medicine and their knowledge of specific therapies: 8-Year follow-up at an academic medical center.
      ]. Healthcare providers rely on clinical practice guidelines (CPGs) to provide evidence-based recommendations for the diagnosis, treatment, and management of diseases []; CPGs are of specific value in situations where healthcare providers lack knowledge on topics, such as CAM therapies. To date, no study has determined the quantity nor assessed the quality of CAM recommendations found across CPGs for the treatment and/or management of T2DM, thus this is the present study's objective.

      Methods

      Approach

      A systematic review was undertaken to identify CPGs for the treatment and/or management of T2DM using standard methods [
      • Moher D.
      • Liberati A.
      • Tetzlaff J.
      • Altman D.G.
      Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
      ] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [
      • Brouwers M.C.
      • Kho M.E.
      • Browman G.P.
      • Burgers J.S.
      • Cluzeau F.
      • Feder G.
      • et al.
      AGREE II: advancing guideline development, reporting and evaluation in health care.
      ]. A protocol was registered with PROSPERO, registration number CRD42019132306. Eligible CPGs containing CAM recommendations were assessed by two assessors (KDV and KG) with the widely-used and validated Appraisal of Guidelines for Research & Evaluation (AGREE II) Instrument [
      • Wieland L.S.
      • Manheimer E.
      • Sampson M.
      • Barnabas J.P.
      • Bouter L.M.
      • Cho K.
      • et al.
      Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials.
      ]. The AGREE II instrument consists of 23 items grouped by six domains: scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability, and editorial independence [
      • Wieland L.S.
      • Manheimer E.
      • Sampson M.
      • Barnabas J.P.
      • Bouter L.M.
      • Cho K.
      • et al.
      Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials.
      ]. These CPGs were assessed twice using AGREE II; first to assess the quality of all recommendations overall, and second to assess the quality of only CAM recommendations.

      Eligibility criteria

      Eligibility criteria for CPGs were based on the Population, Intervention, Comparison and Outcome (PICO) framework. Eligible populations were adults aged 19 years and older and diagnosed with T2DM. For interventions, CPGs were deemed eligible if they provided recommendations for the treatment and/or management of T2DM. We then reviewed each eligible CPG to identify whether any recommendations for CAM therapies were provided. For the purpose of this review, we defined what constituted a CAM therapy based on Cochrane Complementary Medicine's operational definition []. Only eligible CPGs containing CAM recommendations were assessed using the AGREE II instrument, and comparisons were made between the quality of overall and CAM recommendations across the six domains. Outcomes included all AGREE II scores which reflect CPG content and format. The following eligibility criteria were also applied to define eligible CPGs: published in 2009 or later; written in the English language; and either publicly available or orderable through our library system. Publications in the form of consensus statements, protocols, abstracts, conference proceedings, letters, or editorials; based on primary studies that evaluated T2DM management or treatment; or focused on T2DM curriculum, education, training, research, professional certification, or performance, were all ineligible. CPGs designed for highly-specialized populations, such as individuals with T2DM in the context of other comorbidities were also deemed ineligible, as this review sought to capture general T2DM CPG recommendations. Finally, patient versions of CPGs and consensus-based CPGs were excluded, as they are not designed to be assessed by AGREE II. If multiple versions of the same CPG were found in the search results, the most updated version was assessed, and all previous versions were excluded.

      Searching and screening

      MEDLINE, EMBASE, and CINAHL were searched on August 15, 2020, from 2009 to August 14, 2020, inclusive. The search strategy included indexed headings and keywords that reflect terms commonly used in the literature to refer to diabetes. A sample search strategy is provided in Supplementary File 1. We also searched the Guidelines International Network, a repository of CPGs [
      Welcome to G-I-N — guidelines international Network.
      ], using keyword searches based on the eligibility criteria including “diabetes”. Next, we searched the National Center for Complementary and Integrative Health website which contained a list of CAM CPGs []. KDV and KG screened titles and abstracts from all sources and screened full-text items to confirm eligibility. JYN reviewed the screened titles, abstracts, and full-text items to standardize screening, and met with KDV and KG to discuss and resolve any discrepancies that arose.

      Data extraction and analysis

      The following data were extracted from each CPG and summarized: date of publication, country of the CPG, type of organization that published the CPG (i.e., academic institutions, government agencies, disease-specific foundations, or professional associations or societies), and what CAM therapies were mentioned and/or recommended in the CPG. We determined that a CPG made “mention” of CAM when there was no recommendation provided associated with the given therapy in question. In contrast, we defined a “recommendation” of CAM to represent an evidence-informed suggestion or proposal made by the CPG panel regarding the best course of action surrounding the given therapy in question. CAM funding sources and whether any CAM providers were part of the CPG panel were collected from CPGs containing CAM recommendations. Most data were available in the CPG, however, the website of each developer was also visited and reviewed for any additional details not captured in the main CPG document.

      Guideline quality assessment

      Prior to quality assessing eligible CPGs containing CAM recommendations [
      • Wieland L.S.
      • Manheimer E.
      • Sampson M.
      • Barnabas J.P.
      • Bouter L.M.
      • Cho K.
      • et al.
      Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials.
      ], all three authors participated in a pilot test whereby we independently assessed three CPGs using the AGREE II instrument; we then met to discuss and standardize scoring. Then, KDV and KG independently assessed all eligible CPGs containing CAM recommendations twice (i.e., once for the overall CPG and once for the CAM sections) for 23 items across six domains using a seven-point Likert scale from strongly disagree (1) to strongly agree (7) that the item is met, rated the overall quality of each CPG (1–7), and recommended for or against the use of each CPG. CAM sections were evaluated using modified AGREE II questions provided in Supplementary File 2. All three authors met to discuss and resolve any discrepancies. Average appraisal scores, average overall assessments, and scaled domain percentages for each CPG were calculated for comparison. Average appraisal scores for each CPG were calculated by taking the average of the ratings for the 23 AGREE II items, followed by taking the average of this value for both appraisers. Average overall assessments were calculated as the average of both appraisers' “overall guideline assessment” scores for each CPG. Scaled domain percentages were generated by adding both appraisers' ratings of items within each domain, and scaling by maximum and minimum possible domain scores before converting into a percentage.

      Results

      Search results (Fig. 1)

      Combined searches retrieved 2875 items, of which 2609 were unique; a total of 2530 items were eliminated by title/abstract screening, leaving 79 items for full-text review. Of those, 52 were not eligible for the following reasons: CPG summary (n = 10), not published in English (n = 7), review of CPGs (n = 6), position statement (n = 5), duplicate/part of the same CPG (n = 4), highly-specialized target populations (n = 4), CPG not focused on treatment/management (n = 3), editorial (n = 3), CPGs not focused on T2DM (n = 2), irretrievable (n = 2), newer/updated version of CPG available (n = 2), consensus-based CPG (n = 1), patient version of CPG (n = 1), systematic review (n = 1), and withdrawn CPG (n = 1). This resulted in a total of 27 eligible CPGs [
      • Matthaei S.
      • Bierwirth R.
      • Fritsche A.
      • Gallwitz B.
      • Häring H.-U.
      • Joost H.-G.
      • et al.
      Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.
      ,
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Malaysian Dietitians’ Association
      ,
      • Mallery L.H.
      • Ransom T.
      • Steeves B.
      • Cook B.
      • Dunbar P.
      • Moorhouse P.
      Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the diabetes care program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program.
      ,
      • Diabetes Australia
      Royal Australian college of general practitioners. General practice management of type 2 diabetes.
      ,
      International Diabetes Federation Guideline Development Group
      Global guideline for type 2 diabetes.
      ,
      • Handelsman Y.
      • Bloomgarden Z.T.
      • Grunberger G.
      • Umpierrez G.
      • Zimmerman R.S.
      • Bailey T.S.
      • et al.
      American association of clinical endocrinologists and American college of endocrinology – clinical practice guidelines for developing A diabetes mellitus comprehensive care plan – 2015.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      National institute for health and care excellence (NICE)
      Type 2 diabetes in adults: management.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Ministry of Public Health Qatar
      The diagnosis and management of type 2 diabetes in adults and the elderly.
      ,
      • Qaseem A.
      • Barry M.J.
      • Humphrey L.L.
      • Forciea M.A.
      Clinical guidelines committee of the American college of physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American college of physicians.
      ,
      • Shera A.S.
      • Basit A.
      • Team P.
      Pakistan's recommendations for optimal management of diabetes from Primary to Tertiary care level (PROMPT).
      ,
      • Guidelines 2018
      ,
      • Silver B.
      • Ramaiya K.
      • Andrew S.B.
      • Fredrick O.
      • Bajaj S.
      • Kalra S.
      • et al.
      EADSG guidelines: insulin therapy in diabetes.
      ,
      • Hamdy O.
      • Ganda O.P.
      • Gabbay R.A.
      Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D.
      ,
      • Munshi M.
      • Blair E.
      • Ganda O.P.
      Guideline for the care of the older adult with diabetes.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Jia W.
      • Weng J.
      • Zhu D.
      • Ji L.
      • Lu J.
      • Zhou Z.
      • et al.
      Standards of medical care for type 2 diabetes in China 2019.
      ,
      • LeRoith D.
      • Biessels G.J.
      • Braithwaite S.S.
      • Casanueva F.F.
      • Draznin B.
      • Halter J.B.
      • et al.
      Treatment of diabetes in older adults: an endocrine society∗ clinical practice guideline.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Kim M.K.
      • Ko S.-H.
      • Kim B.-Y.
      • Kang E.S.
      • Noh J.
      • Kim S.-K.
      • et al.
      2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea.
      ,
      • Araki E.
      • Goto A.
      • Kondo T.
      • Noda M.
      • Noto H.
      • Origasa H.
      • et al.
      Japanese clinical practice guideline for diabetes 2019.
      ,
      • Bertoluci M.C.
      • Salles J.E.N.
      • Silva-Nunes J.
      • Pedrosa H.C.
      • Moreira R.O.
      • da Silva Duarte R.M.C.
      • et al.
      Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ,
      • Joslin Diabetes
      Clinical guideline for pharmacological management of adults with type 2 diabetes.
      , ], of which 11 were found to make mention of CAM therapies [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Diabetes Australia
      Royal Australian college of general practitioners. General practice management of type 2 diabetes.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Hamdy O.
      • Ganda O.P.
      • Gabbay R.A.
      Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D.
      ,
      • Munshi M.
      • Blair E.
      • Ganda O.P.
      Guideline for the care of the older adult with diabetes.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Jia W.
      • Weng J.
      • Zhu D.
      • Ji L.
      • Lu J.
      • Zhou Z.
      • et al.
      Standards of medical care for type 2 diabetes in China 2019.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]; seven of these 11 CPGs made CAM therapy recommendations [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ].

      Guideline characteristics (Table 1)

      Eligible CPGs were published from 2009 to 2020, with first authors originating from the United States (n = 7), Canada (n = 2), Malaysia (n = 2), the United Kingdom (n = 2), Australia (n = 1), Belgium (n = 1), China (n = 1), Colombia (n = 1), Germany (n = 1), India (n = 1), Japan (n = 1), Pakistan (n = 1), Poland (n = 1), Qatar (n = 1), South Korea (n = 1), Sweden (n = 1), and Uganda (n = 1). Additionally, one CPG originated from both Brazil and Portugal. CPGs were funded and/or developed by professional associations or societies (n = 26), and an international agency (n = 1). Eleven CPGs made mention of CAM. These CAMs included DHSs (n = 8), special diets (n = 5), yoga (n = 3), TCM (n = 2), acupuncture (n = 2), manual therapies (n = 2), aromatherapy (n = 1), Ayurveda (n = 1), meditation (n = 1), naturopathy (n = 1), pranayama (n = 1), psychological intervention (n = 1), relaxation techniques (n = 1), Siddha (n = 1), tai chi (n = 1), and unani (n = 1). Recommendations relating to CAM were made in seven CPGs and included DHSs (n = 5), special diets (n = 3), psychological intervention (n = 1), and yoga (n = 1). CAM funding sources were not identified in any of the CPGs. One CPG included two CAM providers including a chiropractor and dietician as part of the CPG panel [
      • Guidelines 2018
      ], while the others did not. We provide a summary of CAM recommendations made across eligible CPGs for the benefit of clinicians and researchers, in Fig. 2.
      Table 1Characteristics of eligible guidelines.
      GuidelineCountryDeveloperGuideline topic
      German Diabetes Association 2009 [
      • Matthaei S.
      • Bierwirth R.
      • Fritsche A.
      • Gallwitz B.
      • Häring H.-U.
      • Joost H.-G.
      • et al.
      Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.
      ]
      GermanyGerman Diabetes AssociationMedical antihyperglycaemic treatment of type 2 diabetes
      SIGN 2010 [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ]
      ScotlandHealthcare Improvement Scotland, Scottish Intercollegiate Guidelines Network (SIGN)Management of type 1 and type 2 diabetes
      Malaysian Dietitians' Association 2013 [
      • Malaysian Dietitians’ Association
      ]
      MalaysiaMalaysian Dietitians' AssociationMedical nutrition therapy for type 2 diabetes
      Mallery 2013 [
      • Mallery L.H.
      • Ransom T.
      • Steeves B.
      • Cook B.
      • Dunbar P.
      • Moorhouse P.
      Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the diabetes care program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program.
      ]
      CanadaDiabetes Care Program of Nova ScotiaTreating frail older adults with type 2 diabetes
      Diabetes Australia 2014 [
      • Diabetes Australia
      Royal Australian college of general practitioners. General practice management of type 2 diabetes.
      ]
      AustraliaRoyal Australian College of General Practitioners, Diabetes AustraliaManagement of type 2 diabetes in general practice
      International Diabetes Federation 2014 [
      International Diabetes Federation Guideline Development Group
      Global guideline for type 2 diabetes.
      ]
      BelgiumInternational Diabetes FederationGlobal guideline for type 2 diabetes
      Handelsman 2015 [
      • Handelsman Y.
      • Bloomgarden Z.T.
      • Grunberger G.
      • Umpierrez G.
      • Zimmerman R.S.
      • Bailey T.S.
      • et al.
      American association of clinical endocrinologists and American college of endocrinology – clinical practice guidelines for developing A diabetes mellitus comprehensive care plan – 2015.
      ]
      United StatesAmerican Association of Clinical Endocrinologists and American College of EndocrinologyDeveloping a diabetes mellitus comprehensive care plan
      Ministry of Health Malaysia 2015 [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]
      MalaysiaMalaysian Endocrine and Metabolic Society, Ministry of Health Malaysia, Academy of Medicine Malaysia, Diabetes Malaysia, Family Medicine Specialists Association of MalaysiaIdentification, diagnosis, and management of type 2 diabetes
      NICE 2015 [
      National institute for health and care excellence (NICE)
      Type 2 diabetes in adults: management.
      ]
      United KingdomNational Institute for Health and Care Excellence (NICE)Management of type 2 diabetes in adults
      Aschner 2016 [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ]
      ColumbiaColumbia MedicaPrevention, early detection, diagnosis, management and follow up of type 2 diabetes in adults
      Ministry of Public Health Qatar 2017 [
      • Ministry of Public Health Qatar
      The diagnosis and management of type 2 diabetes in adults and the elderly.
      ]
      QatarMinistry of Public Health QatarDiabetes mellitus type 2 in adults & elderly
      Qaseem 2017 [
      • Qaseem A.
      • Barry M.J.
      • Humphrey L.L.
      • Forciea M.A.
      Clinical guidelines committee of the American college of physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American college of physicians.
      ]
      United StatesAmerican College of PhysiciansOral Pharmacologic Treatment of Type 2 Diabetes
      Shera 2017 [
      • Shera A.S.
      • Basit A.
      • Team P.
      Pakistan's recommendations for optimal management of diabetes from Primary to Tertiary care level (PROMPT).
      ]
      PakistanNational Association of Diabetes Educators of PakistanManagement of diabetes from primary to tertiary care
      Canadian Diabetes Association 2018 [
      • Guidelines 2018
      ]
      CanadaCanadian Diabetes AssociationPrevention and management of diabetes in Canada
      East African Diabetes Study Group 2018 [
      • Silver B.
      • Ramaiya K.
      • Andrew S.B.
      • Fredrick O.
      • Bajaj S.
      • Kalra S.
      • et al.
      EADSG guidelines: insulin therapy in diabetes.
      ]
      UgandaEast African Diabetes Study Group (EADSG)Insulin therapy in diabetes
      Hamdy 2018 [
      • Hamdy O.
      • Ganda O.P.
      • Gabbay R.A.
      Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D.
      ]
      United StatesJoslin Diabetes CenterClinical nutrition guideline for overweight and obese adults with type 2 diabetes, prediabetes, or high risk for developing type 2 diabetes
      Munshi 2018 [
      • Munshi M.
      • Blair E.
      • Ganda O.P.
      Guideline for the care of the older adult with diabetes.
      ]
      United StatesJoslin Diabetes CenterCare for older adults with diabetes
      Research Society for the Study of Diabetes in India (RSSDI) 2018 [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]
      IndiaResearch Society for Study of Diabetes in India (RSSDI)Management of type 2 diabetes in India
      Chinese Diabetes Society 2019 [
      • Jia W.
      • Weng J.
      • Zhu D.
      • Ji L.
      • Lu J.
      • Zhou Z.
      • et al.
      Standards of medical care for type 2 diabetes in China 2019.
      ]
      ChinaChinese Diabetes SocietyMedical care for type 2 diabetes in China
      Endocrine Society 2019 [
      • LeRoith D.
      • Biessels G.J.
      • Braithwaite S.S.
      • Casanueva F.F.
      • Draznin B.
      • Halter J.B.
      • et al.
      Treatment of diabetes in older adults: an endocrine society∗ clinical practice guideline.
      ]
      United StatesEndocrine SocietyTreatment of diabetes in older adults
      European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019 [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]
      SwedenEuropean Society of CardiologyDiabetes, pre-diabetes, and cardiovascular disease
      Korean Diabetes Association 2019 [
      • Kim M.K.
      • Ko S.-H.
      • Kim B.-Y.
      • Kang E.S.
      • Noh J.
      • Kim S.-K.
      • et al.
      2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea.
      ]
      South KoreaKorean Diabetes AssociationDiagnosis and management of type 2 diabetes in Korea
      Japan Diabetes Society 2019 [
      • Araki E.
      • Goto A.
      • Kondo T.
      • Noda M.
      • Noto H.
      • Origasa H.
      • et al.
      Japanese clinical practice guideline for diabetes 2019.
      ]
      JapanJapan Diabetes Society (JDS)Management of diabetes
      Bertoluci 2020 [
      • Bertoluci M.C.
      • Salles J.E.N.
      • Silva-Nunes J.
      • Pedrosa H.C.
      • Moreira R.O.
      • da Silva Duarte R.M.C.
      • et al.
      Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.
      ]
      Brazil, PortugalSociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Endocrinologia e Matabologia (SBEM), Sociedade Portuguesa de Diabetologia (SPD), Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM)Management of hyperglycemia in type 2 diabetes mellitus
      Diabetes Poland 2020 [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]
      PolandDiabetes PolandManagement of diabetic patients
      Ganda 2020 [
      • Joslin Diabetes
      Clinical guideline for pharmacological management of adults with type 2 diabetes.
      ]
      United StatesJoslin Diabetes CenterPharmacological management of adults with type 2 diabetes
      Hafida 2020 []United StatesJoslin Diabetes CenterManagement of adults with diabetes
      Figure 2
      Figure 2Summary of CAM recommendations in clinical practice guidelines.

      Guidelines mentioning CAM without recommendations

      Of the 11 eligible CPGs making mention of CAM, four did not provide any CAM recommendations. One of these CPGs briefly mentioned the Mediterranean diet and complementary medicine in general [
      • Diabetes Australia
      Royal Australian college of general practitioners. General practice management of type 2 diabetes.
      ]. The authors provided a short sentence about why the Mediterranean diet is beneficial, in addition to one small section about the use of complementary medicine, some examples of complementary medicine, and that CAM use should be assessed in patients. Another CPG included tai chi and yoga in a list of activities that may be appropriate for older adults [
      • Munshi M.
      • Blair E.
      • Ganda O.P.
      Guideline for the care of the older adult with diabetes.
      ]. The third CPG briefly discussed the benefits and disadvantages of a number of special diets and nutritional supplements, such as the Mediterranean diet, the Dietary Approaches to Stop Hypertension (DASH) diet, vegan & vegetarian diets, multivitamin supplements, and herbal supplements or spices [
      • Hamdy O.
      • Ganda O.P.
      • Gabbay R.A.
      Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D.
      ]. The fourth CPG included three short paragraphs outlining TCM and its beneficial effects using an example from an experimental study, while also briefly stating that nutritional supplements may be useful [
      • Jia W.
      • Weng J.
      • Zhu D.
      • Ji L.
      • Lu J.
      • Zhou Z.
      • et al.
      Standards of medical care for type 2 diabetes in China 2019.
      ].

      Average appraisal scores and average overall assessments: overall guideline (Table 2)

      The average appraisal scores for the 7 CPGs that included CAM recommendations ranged from 3.6 to 5.8 on the seven-point Likert scale; 6 CPGs exceeded an average appraisal score of 4.0. Average overall assessments for the 7 CPGs ranged from 3.5 to 6.5; with 4 exceeding an overall score of 5.0.
      Table 2Average appraisal scores and average overall assessments of each guideline.
      GuidelineMetricAppraiser 1Appraiser 2AverageStandard Deviation
      SIGN 2010 [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ] (Overall)
      Appraisal Score5.25.75.40.4
      Overall Assessment6.06.06.00.0
      SIGN 2010 [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ] (CAM section)
      Appraisal Score4.64.14.30.3
      Overall Assessment5.04.05.50.7
      Ministry of Health Malaysia 2015 [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ] (Overall)
      Appraisal Score4.15.44.70.9
      Overall Assessment5.05.05.00.0
      Ministry of Health Malaysia 2015 [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ] (CAM section)
      Appraisal Score2.83.02.90.2
      Overall Assessment4.03.03.50.7
      Aschner 2016 [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ] (Overall)
      Appraisal Score4.35.14.70.6
      Overall Assessment4.05.04.50.7
      Aschner 2016 [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ] (CAM section)
      Appraisal Score2.82.62.70.2
      Overall Assessment3.03.03.00.0
      Canadian Diabetes Association 2018 [
      • Guidelines 2018
      ] (Overall)
      Appraisal Score5.36.35.80.8
      Overall Assessment6.06.06.00.0
      Canadian Diabetes Association 2018 [
      • Guidelines 2018
      ] (CAM section)
      Appraisal Score4.64.84.70.1
      Overall Assessment6.05.05.50.7
      Research Society for the Study of Diabetes in India (RSSDI) 2018 [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ] (Overall)
      Appraisal Score3.95.24.51.0
      Overall Assessment5.05.05.00.0
      Research Society for the Study of Diabetes in India (RSSDI) 2018 [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ] (CAM section)
      Appraisal Score3.34.13.70.6
      Overall Assessment5.04.04.50.7
      European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019 [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ] (Overall)
      Appraisal Score3.75.14.41.0
      Overall Assessment4.05.04.50.7
      European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019 [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ] (CAM section)
      Appraisal Score2.63.12.90.4
      Overall Assessment3.03.03.00.0
      Diabetes Poland 2020 [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ] (Overall)
      Appraisal Score3.24.03.60.6
      Overall Assessment3.04.03.50.7
      Diabetes Poland 2020 [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ] (CAM section)
      Appraisal Score2.52.82.60.2
      Overall Assessment3.03.03.00.0

      Average appraisal scores and average overall assessments: CAM sections (Table 2)

      The average appraisal scores for the 7 CPGs ranged from 2.6 to 4.7 on the seven-point Likert scale; two CPGs exceeded an average appraisal score of 4.0. Average overall assessments for the 7 CPGs ranged from 3.0 to 5.5, with 2 CPGs exceeding a score of 5.0.

      Overall recommendations: overall guideline (Table 3)

      Four of the CPGs were recommended by both appraisers [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Three CPGs were recommended by one appraiser and recommended with modifications by the other appraiser [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ].
      Table 3Overall recommendations for use of appraised guidelines.
      GuidelineOverall GuidelineCAM Section
      Appraiser 1Appraiser 2Appraiser 1Appraiser 2
      SIGN 2010 [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ]
      YesYesYesNo
      Ministry of Health Malaysia 2015 [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]
      YesYesYes with modificationsNo
      Aschner 2016 [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ]
      Yes with modificationsYesYes with modificationsNo
      Canadian Diabetes Association 2018 [
      • Guidelines 2018
      ]
      YesYesYesNo
      Research Society for the Study of Diabetes in India (RSSDI) 2018 [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]
      YesYesYes with modificationsNo
      European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019 [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]
      Yes with modificationsYesYes with modificationsYes
      Diabetes Poland 2020 [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]
      Yes with modificationsYesYes with modificationsNo

      Overall recommendations: CAM sections (Table 3)

      None of the CPGs were recommended by both appraisers. One CPG was recommended by one appraiser and recommended with modifications by the other appraiser [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ], four were recommended with modifications by one appraiser and not recommended by the other appraiser [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], and two were recommended by one appraiser and not recommended by the other appraiser [
      • Guidelines 2018
      ].

      Scaled domain percentage quality assessment (Table 4)

      With regards to scaled domain percentages of the overall CPGs, scope and purpose scores ranged from 97.2% to 83.3%, stakeholder involvement scores ranged from 88.9% to 47.2%, rigour of development scores ranged from 80.2% to 28.1%, clarity-of-presentation scores ranged from 97.2% to 69.4%, applicability scores ranged from 77.1% to 27.1%, and editorial independence scores ranged from 75.0% to 0.0%. For the CAM sections, scope and purpose scores ranged from 94.4% to 69.4%, stakeholder involvement scores ranged from 63.9% to 8.3%, rigour of development scores ranged from 57.3% to 19.8%, clarity-of-presentation scores ranged from 80.6% to 11.1%, applicability scores ranged from 47.9% to 2.1%, and editorial independence scores ranged from 70.8% to 0.0%.
      Table 4Scaled domain percentages for appraisers of each guideline.
      GuidelineDomain score (%)
      Scope and purposeStakeholder involvementRigour of developmentClarity of presentationApplicabilityEditorial Independence
      SIGN 2010 [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ]
      Overall Guideline94.488.968.891.777.18.3
      CAM Section94.452.857.355.647.98.3
      Ministry of Health Malaysia 2015 [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]
      Overall Guideline88.977.847.977.858.341.7
      CAM Section75.016.727.144.48.341.7
      Aschner 2016 [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ]
      Overall Guideline97.263.942.780.662.545.8
      CAM Section77.822.221.811.112.545.8
      Canadian Diabetes Association 2018 [
      • Guidelines 2018
      ]
      Overall Guideline94.488.980.297.254.270.8
      CAM Section83.363.963.580.625.070.8
      Research Society for the Study of Diabetes in India (RSSDI) 2018 [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]
      Overall Guideline83.361.139.669.462.575.0
      CAM Section69.416.737.558.335.475.0
      European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) 2019 [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]
      Overall Guideline86.147.240.694.441.766.7
      CAM Section86.18.319.844.42.166.7
      Diabetes Poland 2020 [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]
      Overall Guideline83.347.228.188.927.10.0
      CAM Section72.216.722.944.410.40.0

      Scope and purpose

      The overall objectives were well-defined in all CPGs. Scores for the CAM sections of the CPGs for the objectives were the same as the overall CPGs. The health questions were also well-presented typically including the intervention or action, the outcome, and the population. The health questions were easy to identify in most CPGs [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ], while a few were difficult to find [
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. In four CPGs, scores for the CAM sections for the health questions were similar to the rest of the CPG [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. The others did not clearly mention CAM interventions in the questions [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. The population to whom the CPG was meant to apply was also well-stated. All CPGs referred to the target population as being diabetic and sometimes also those at risk of developing diabetes, and in most instances, the target population was only referring to adults. Although severity and comorbidities were not explicitly stated, they were identifiable throughout the CPGs. Three CPGs mentioned that they were designed for populations in certain countries [
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. None of the CPGs gave specific ages and there was no mention of gender. Considering that the population is the same for the whole CPG, scores of the CAM sections were the same as the rest of the CPG.

      Stakeholder involvement

      All CPGs included the names of the development group. Most CPGs also included the discipline, institution, and location of the development group members, while one did not [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Three CPGs clearly identified the role of the members [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Two CPGs mentioned that their CPG development groups were interdisciplinary or had representation from different subspecialties [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. One CPG did not provide details of the development group in English [
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. Four CPGs did not have any CAM members as a part of the development group [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. One CPG included two CAM providers on their development panel, including a chiropractor and a dietician [
      • Guidelines 2018
      ]. One CPG identified those who worked on the CAM section of the CPG but only stated their names [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Four CPGs did not seek the views and preferences of the target population [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. Two CPGs included patient representatives in the CPG development group, but did not include the methods for including them or how their perspectives were taken into consideration [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ], while one CPG provided their methods and strategy to gain target population perspectives [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ]. For those CPGs that did seek target population preferences, the CAM sections of the CPGs scored similar or slightly lower since it was assumed the preferences were sought for the whole CPG, however, there was no discussion of specific views or preferences of CAM users. Target users were clearly defined by three CPGs as “all healthcare workers involved” [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ], while one CPG also more specifically stated “primary care physicians across India” [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. The three other CPGs did not explicitly state the users [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. How the CPG is to be used by the user was clearly stated in four CPGs [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. Only one CPG specifically mentioned dietitians as CAM users of the CPG [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]. Overall users were the same for the overall CPG; however, since CAM users were not clearly defined, the CAM sections scored slightly lower.

      Rigour of development

      Two CPGs provided detailed search methods [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Guidelines 2018
      ], however one did not include a full search strategy [
      • Guidelines 2018
      ]. Two CPGs only provided the database used and/or the period that was searched [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. The methods to search for evidence were not provided in 2 CPGs [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. The criteria for selecting the evidence was not provided for three CPGs [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], while others provided little information [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. One CPG provided search methods and criteria for selecting evidence through a link, which was inaccessible at the time of assessment [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ]. The scores for the CAM section were also the same for this category. The strengths and limitations of the body of evidence that were collected were described in most CPGs [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], but one CPG did not describe how the evidence was evaluated [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. The scores for the CAM section were similar for this section. Most CPGs had little to no information on the methods of formulating the recommendations [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], while one CPG explained how evidence was used in the recommendation developing process [
      • Guidelines 2018
      ]. The scores for the CAM section were the same for this category. All CPGs considered some health benefits, side effects, and/or risks to some extent when formulating their recommendations. Sometimes they were not very easily identifiable [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. The CAM sections of the CPGs received a lower score since they generally had less detailed benefits and harms and sometimes only covered one or the other. One CPG, however, did not include this information for its CAM section [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. All CPGs provided an explicit link between their recommendations and the supporting evidence, with links to the references and/or with evidence in the accompanying paragraphs. How the evidence was used to form the recommendations was not always clear. The CAM sections received similar scores. One CPG only had a link to references but no accompanying paragraph for the CAM sections [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. Most CPGs stated that they were externally reviewed by experts prior to publication, but did not include some of the following information: outcomes of the review, purpose of the review, or methods employed for the external review [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. Two CPGs did not state whether they were externally reviewed [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. None of the CPGs that were externally reviewed mentioned that there were CAM experts as a part of the reviewers. Most CPGs stated that the CPG will be updated. One provided a timeframe and methods [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ], while others provided only a timeframe [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. One CPG only stated that it will be “updated regularly” [
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. Two CPGs had no information about a protocol for updating [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. These scores were the same for the overall CPGs and CAM sections.

      Clarity of presentation

      Generally, the CPGs offered specific and unambiguous recommendations, however, in all CPGs, some recommendations lacked one or more of the following details: identification of the purpose, relevant population, or caveats. The scores for the CAM sections were slightly lower than the rest of the CPG for most CPGs. All CPGs scored highly in presenting different options for the management of the condition or health issue, thus contributing to this high scaled domain percentage. With respect to the CAM section scores, three CPGs had provided information about more CAM therapies [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ], while the others had fewer options [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]; one primarily only provided warnings against CAM use [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]. Key recommendations were also easily identifiable, but only two had a key recommendation section [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. The other CPGs had sections with grouped recommendations but no specific section for key recommendations [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. The CAM sections of the CPGs scored similarly to the rest of the CPG, except for four CPGs in which the CAM recommendations were not separated or easily identifiable [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ].

      Applicability

      There was limited discussion about facilitators and barriers in the CPGs, some of which had specific implementation sections, otherwise spread out through the CPG. One CPG had more discussion on dissemination and implementation strategies [
      • Guidelines 2018
      ]. All CPGs included advice and/or tools to support the implementation of the recommendations. Four CPGs contained little discussion on resource implications [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], while three had more detailed information on the topic [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Two CPGs provided detailed monitoring and auditing criteria [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]; one of these CPGs only provided this for a subset of the recommendations made [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Other CPGs either did not explicitly state auditing criteria [
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ], or were missing some information such as the frequency or specific measurements to monitor [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ]. The CAM sections scored low as there was less or no discussion of facilitators/barriers to implementation, tools, resource implications, or auditing criteria specific to CAM recommendations [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ].

      Editorial independence

      Of the five CPGs that stated the funding body, four did not declare whether it influenced the content of the CPG [
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ,
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ], and one was internally funded [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Two CPGs did not state their source of funding [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. Two CPGs stated competing interests were present but were missing some of the following: methods, how the competing interests influenced the CPG, or a list of the competing interests that were found [
      • Guidelines 2018
      ,
      • Cosentino F.
      • Grant P.J.
      • Aboyans V.
      • Bailey C.J.
      • Ceriello A.
      • Delgado V.
      • et al.
      2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
      ]. One CPG stated no competing interests but did not provide any further details [
      • Bajaj S.
      RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
      ]. Two CPGs stated that competing interests were available upon request [
      • Scottish Intercollegiate Guidelines Network
      Management of diabetes: a national clinical guideline.
      ,
      HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
      Management of type 2 diabetes mellitus.
      ] and two provided them in languages other than English [
      • Aschner P.M.
      • Muñoz O.M.
      • Girón D.
      • García O.M.
      • Fernández-Ávila D.G.
      • Casas L.Á.
      • et al.
      Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
      ,
      • Araszkiewicz A.
      • Bandurska-Stankiewicz E.
      • Budzyński A.
      • Cypryk K.
      • Czech A.
      • Czupryniak L.
      • et al.
      2020 Guidelines on the management of diabetic patients.
      ]. The scores of the CAM sections for this domain were the same as the overall CPG.

      Discussion

      The purpose of the present review was to identify the quantity and assess the quality of CAM recommendations in CPGs for the treatment and/or management of T2DM. This study identified seven CPGs published between 2010 and 2020 that made CAM therapy recommendations. Quality varied greatly across CPGs overall and by domain, as assessed by the AGREE II instrument. In assessing the overall CPGs, all CPGs scored 3.0 or higher for both the average appraisal score and the average overall assessment. In assessing the CAM section of each CPG, all CPGs scored over 2.0 for both the average appraisal score and the average overall assessment (1 = strongly disagree; 7 = strongly agree that criteria are met).
      To our knowledge, this is the first study to explore the nature of CAM therapy recommendations in CPGs for the treatment and/or management of T2DM. With respect to comparative literature, a number of reviews have assessed the quality of diabetes CPGs. One study assessed seven T2DM CPGs and found similar scores, whereby the scope and purpose and clarity of presentation domains received the highest scores, while the rigour of development and applicability domains received the lowest scores [
      • Anwer M.A.
      • Al-Fahed O.B.
      • Arif S.I.
      • Amer Y.S.
      • Titi M.A.
      • Al-Rukban M.O.
      Quality assessment of recent evidence-based clinical practice guidelines for management of type 2 diabetes mellitus in adults using the AGREE II instrument.
      ]. Another study also assessed seven T2DM CPGs and reported similar findings with respect to the clarity of presentation and scope and purpose domains receiving the highest scores, and the rigour of development and editorial independence domains receiving the lowest scores [
      • Ng J.Y.
      • Verma K.D.
      Identifying the quantity and assessing the quality of clinical practice guidelines for the treatment and management of type 2 diabetes: a systematic review.
      ]. Yet another study evaluated 21 paediatric T2DM CPGs and found that the clarity of presentation domain scored the highest and the rigour of development and editorial independence domains scored the lowest [
      • Bhatt M.
      • Nahari A.
      • Wang P.-W.
      • Kearsley E.
      • Falzone N.
      • Chen S.
      • et al.
      The quality of clinical practice guidelines for management of pediatric type 2 diabetes mellitus: a systematic review using the AGREE II instrument.
      ]. Lastly, one study that assessed the quality of 13 gestational diabetes CPGs found that the scope and purpose and clarity of presentation domains had the highest scores, while the rigour of development, stakeholder involvement, and editorial independence domains received the lowest scores [
      • Zhang M.
      • Zhou Y.
      • Zhong J.
      • Wang K.
      • Ding Y.
      • Li L.
      • et al.
      Quality appraisal of gestational diabetes mellitus guidelines with AGREE II: a systematic review.
      ]. Collectively, the order of AGREE II domain scores reported by each of these aforementioned studies is similar to our study's findings. With respect to the overall quality of CPGs, some of these studies reported most CPGs to have high quality [
      • Anwer M.A.
      • Al-Fahed O.B.
      • Arif S.I.
      • Amer Y.S.
      • Titi M.A.
      • Al-Rukban M.O.
      Quality assessment of recent evidence-based clinical practice guidelines for management of type 2 diabetes mellitus in adults using the AGREE II instrument.
      ,
      • Zhang M.
      • Zhou Y.
      • Zhong J.
      • Wang K.
      • Ding Y.
      • Li L.
      • et al.
      Quality appraisal of gestational diabetes mellitus guidelines with AGREE II: a systematic review.
      ], while others reported most to have low/moderate quality [
      • Bhatt M.
      • Nahari A.
      • Wang P.-W.
      • Kearsley E.
      • Falzone N.
      • Chen S.
      • et al.
      The quality of clinical practice guidelines for management of pediatric type 2 diabetes mellitus: a systematic review using the AGREE II instrument.
      ], indicating that variability in quality across CPGs is not uncommon.
      A number of studies have also identified the quantity and assessed the quality of CAM recommendations found in CPGs across a wide-range of other common diseases/conditions. Reviews assessing CAM recommendations in low back pain and depression CPGs both found that the majority of CPGs had CAM recommendations, and their quality was the same or lower than those of the overall CPG [
      • Ng J.Y.
      • Mohiuddin U.
      Quality of complementary and alternative medicine recommendations in low back pain guidelines: a systematic review.
      ,
      • Ng J.Y.
      • Nazir Z.
      • Nault H.
      Complementary and alternative medicine recommendations for depression: a systematic review and assessment of clinical practice guidelines.
      ]. Another study found that only one-third of multiple sclerosis CPGs provided CAM recommendations, and that they scored lower than the overall CPG recommendations [
      • Ng J.Y.
      • Kishimoto V.
      Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: a systematic review.
      ]. Yet another review assessed CAM recommendations in rheumatoid arthritis and osteoarthritis CPGs, and found that half of the CPGs contained CAM recommendations, which scored lower than overall recommendations across all domains except for clarity of presentation [
      • Ng J.Y.
      • Azizudin A.M.
      Rheumatoid arthritis and osteoarthritis clinical practice guidelines provide few complementary and alternative medicine therapy recommendations: a systematic review.
      ]. Across cancer-related pain CPGs, CAM section recommendations were also of lower quality than those overall [
      • Ng J.Y.
      • Sharma A.E.
      Guidelines for cancer-related pain: a systematic review of complementary and alternative medicine recommendations.
      ]. Across other conditions, CAM recommendations were virtually absent; for example, across hypertension CPGs, only a single CPG provided CAM recommendations [
      • Ng J.Y.
      • Gilotra K.
      Complementary medicine mention and recommendations are limited across hypertension guidelines: a systematic review.
      ]. Apart from hypertension CPGs, the present review found that proportionately fewer T2DM CPGs provided CAM recommendations in comparison to CPGs of the aforementioned diseases/conditions. Our findings are comparable to these aforementioned studies, with respect to the fact that our CAM section AGREE II scores were also generally the same or lower than overall CPG scores across most if not all of the instrument's domains.
      Given that only one-quarter of CPGs for the treatment and/or management of T2DM provide CAM recommendations, a knowledge gap exists for healthcare providers who seek evidence-based resources to support informed and shared decision-making with their patients who inquire about these therapies. A number of reasons can explain why a lack of high-quality CAM-specific recommendations exist across this subset of CPGs as a number of barriers exist with regards to conducting CAM research. Although the body of literature on CAM and T2DM continues to grow, there is still insufficient information surrounding the effectiveness, efficacy, and safety of many CAM therapies, making it difficult to access rigorous and reliable evidence [
      • Fischer F.H.
      • Lewith G.
      • Witt C.M.
      • Linde K.
      • von Ammon K.
      • Cardini F.
      • et al.
      High prevalence but limited evidence in complementary and alternative medicine: guidelines for future research.
      ]. Some of the barriers to CAM research that have been identified include a lack of the following: access to funding, education/skills in research, CAM journals in mainstream databases, and existing high-quality research/researchers in CAM [
      • Veziari Y.
      • Leach M.J.
      • Kumar S.
      Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review.
      ]. Others have identified skepticism and a lack of familiarity with CAM as barriers to healthcare professionals' ability to effectively counsel patients about CAM therapies [
      • Susilawati D.
      • Sitaresmi M.
      • Handayani K.
      • van de Ven P.
      • null Sutaryo
      • Kaspers G.
      • et al.
      HealthCare providers' and parents' perspectives on complementary alternative medicine in children with cancer in Indonesia.
      ,
      • Wahner-Roedler D.L.
      • Lee M.C.
      • Chon T.Y.
      • Cha S.S.
      • Loehrer L.L.
      • Bauer B.A.
      Physicians' attitudes toward complementary and alternative medicine and their knowledge of specific therapies: 8-Year follow-up at an academic medical center.
      ]. This landscape is changing, however, and more recently published studies have found that an increased number of healthcare practitioners and trainees seek knowledge and education about CAM [
      • Patel S.J.
      • Kemper K.J.
      • Kitzmiller J.P.
      Physician perspectives on education, training, and implementation of complementary and alternative medicine.
      ,
      • Loh K.P.
      • Ghorab H.
      • Clarke E.
      • Conroy R.
      • Barlow J.
      Medical students' knowledge, perceptions, and interest in complementary and alternative medicine.
      ,
      • Templeman K.
      • Robinson A.
      • McKenna L.
      Student identification of the need for complementary medicine education in Australian medical curricula: a constructivist grounded theory approach.
      ,
      • Akan H.
      • Izbirak G.
      • Kaspar E.Ç.
      • Kaya Ç.A.
      • Aydin S.
      • Demircan N.
      • et al.
      Knowledge and attitudes towards complementary and alternative medicine among medical students in Turkey.
      ]. Further research that focusses on translating CAM research knowledge into recommendations that can be incorporated into T2DM CPGs is warranted. Additionally, improving the applicability and implementation of CAM research can increase CAM representation in CPGs. Knowledge of the present review's findings is of value for those who will develop/update future T2DM CPGs; in addition to the AGREE II instrument, numerous resources exist to provide developers with guidance on how to incorporate high-quality CAM recommendations into CPGs [
      • Piggott T.
      • Langendam M.
      • Parmelli E.
      • Adolfsson J.
      • Akl E.A.
      • Armstrong D.
      • et al.
      Bringing two worlds closer together: a critical analysis of an integrated approach to guideline development and quality assurance schemes.
      ,
      • Schünemann H.J.
      • Mustafa R.A.
      • Brozek J.
      • Santesso N.
      • Bossuyt P.M.
      • Steingart K.R.
      • et al.
      GRADE guidelines: 22. The GRADE approach for tests and strategies-from test accuracy to patient-important outcomes and recommendations.
      ,
      • Rosenfeld R.M.
      • Shiffman R.N.
      Clinical practice guideline development manual: a quality-driven approach for translating evidence into action.
      ,
      • Schünemann H.J.
      • Wiercioch W.
      • Etxeandia I.
      • Falavigna M.
      • Santesso N.
      • Mustafa R.
      • et al.
      Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise.
      ,
      • Gagliardi A.R.
      • Armstrong M.J.
      • Bernhardsson S.
      • Fleuren M.
      • Pardo-Hernandez H.
      • Vernooij R.W.M.
      • et al.
      The Clinician Guideline Determinants Questionnaire was developed and validated to support tailored implementation planning.
      ,
      • Scottish Intercollegiate Guidelines Network
      SIGN 50: a guideline developer's handbook.
      , ,
      • Armstrong M.J.
      • Rueda J.-D.
      • Gronseth G.S.
      • Mullins C.D.
      Framework for enhancing clinical practice guidelines through continuous patient engagement.
      ,
      • Blackwood J.
      • Armstrong M.J.
      • Schaefer C.
      • Graham I.D.
      • Knaapen L.
      • Straus S.E.
      • et al.
      How do guideline developers identify, incorporate and report patient preferences? An international cross-sectional survey.
      ].

      Strengths and limitations

      The present review was informed by a comprehensive, systematic search of the literature and adhered to PRISMA guidelines. Eligible CPGs containing CAM recommendations were assessed using the AGREE II instrument, which is widely-regarded as the gold standard for appraising CPGs, as it has been found to be both reliable and valid [
      • Wieland L.S.
      • Manheimer E.
      • Sampson M.
      • Barnabas J.P.
      • Bouter L.M.
      • Cho K.
      • et al.
      Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials.
      ]. The interpretation of these findings may be limited by the fact that CPGs were independently assessed by two appraisers, as opposed to four as recommended by the AGREE II instrument instruction manual. To mitigate this and standardize scoring, all three authors participated in an initial pilot test designed to appraise separate CPGs and standardize the application of the instrument before assessing CPGs included in this study. Although we used Cochrane Complementary Medicine's operational definition to determine whether a given therapy was categorized as CAM [], we acknowledge that consensus surrounding a list of all therapies that make up this category is lacking among healthcare researchers and practitioners alike. For example, certain diets such as the Mediterranean Diet, as well as certain mind-body therapies, such as cognitive behavioural therapy, may or may not be considered CAM. Lastly, another limitation includes our inclusion of only English-language CPGs; as CAMs originate from different regions of the world, the present review may not have captured CPGs published in non-English-speaking countries with traditional medical systems, notably those in Asia, the Middle East, and Africa.

      Conclusions

      This present review identified CAM therapy recommendations across seven CPGs for the treatment and/or management of T2DM. Appraisal of these CPGs with the AGREE II instrument revealed that quality varied within and across CPGs with the CAM sections of the CPG scoring lower or the same in comparison to the overall CPG. Given that CAM therapies for T2DM are only represented in one-quarter of CPGs and are of lower quality, this may leave healthcare providers underprepared to discuss the benefits or risks of CAM therapies with patients. The findings of this review justify the need for further research on translating CAM research knowledge into recommendations that can be incorporated into T2DM CPGs, and are therefore, of value to those who will update/develop this subset of CPGs in the future. The presence of recommendations across T2DM CPGs for commonly used CAM therapies can, in turn, better support informed discussion and shared decision-making between physicians and inquiring patients.

      Ethics approval and consent to participate

      This study involved a systematic review of peer-reviewed literature only; it did not require ethics approval or consent to participate.

      Consent for publication

      All authors consent to this manuscript's publication.

      Availability of data and materials

      All relevant data are included in this manuscript.

      Funding

      This study was unfunded.

      Authors' contributions

      JYN: designed and conceptualized the study, collected and analysed data, co-drafted the manuscript, and gave final approval of the version to be published.
      KDV: assisted with the collection and analysis of data, co-drafted the manuscript, and gave final approval of the version to be published.
      KG: assisted with the collection and analysis of data, revised the manuscript critically, and gave final approval of the version to be published.

      Declaration of competing interest

      The authors declare that they have no competing interests.

      Acknowledgements

      JYN was awarded a Research Scholarship and an Entrance Scholarship from the Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences at McMaster University.

      Appendix A. Supplementary data

      The following are the Supplementary data to this article:

      References

      1. New CDC report: more than 100 million Americans have diabetes or prediabetes | CDC Online Newsroom. Centers for Disease Control and Prevention.
        ([Internet] [cited 2021 Mar 7]. Available from:)
      2. What is diabetes?. Diabetes Canada.
        ([Internet] [cited 2021 Mar 7]. Available from:)
        • Association A.D.
        Diagnosis and classification of diabetes mellitus.
        Diabetes Care. 2014 Jan 1; 37: S81-S90https://doi.org/10.2337/dc14-S081
        • Upadhyay J.
        • Polyzos S.A.
        • Perakakis N.
        • Thakkar B.
        • Paschou S.A.
        • Katsiki N.
        • et al.
        Pharmacotherapy of type 2 diabetes: an update.
        Metabolism. 2018 Jan 1; 78: 13-42https://doi.org/10.1016/j.metabol.2017.08.010
        • Bell R.A.
        • Suerken C.K.
        • Grzywacz J.G.
        • Lang W.
        • et al.
        Complementary and alternative medicine use among adults with diabetes in the United States.
        Alter Ther Health Med. 2006 Oct; 12: 16-22
      3. Complementary, alternative, or integrative health: what's in a name?. NCCIH.
        ([Internet] [cited 2021 Mar 9]. Available from:)
        • Ng J.Y.
        • Boon H.S.
        • Thompson A.K.
        • Whitehead C.R.
        Making sense of “alternative”, “complementary”, “unconventional” and “integrative” medicine: exploring the terms and meanings through a textual analysis.
        BMC Compl Alternative Med. 2016 May 20; 16: 134https://doi.org/10.1186/s12906-016-1111-3
      4. Complementary and alternative medicine for diabetes. Diabetes Canada.
        ([Internet] [cited 2021 Mar 9]. Available from:)
        • Asbaghi O.
        • Fatemeh N.
        • Mahnaz R.K.
        • Ehsan G.
        • Elham E.
        • Behzad N.
        • et al.
        Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
        Pharmacol Res. 2020 Nov 1; 161: 105098https://doi.org/10.1016/j.phrs.2020.105098
        • Dick W.R.
        • Fletcher E.A.
        • Shah S.A.
        Reduction of fasting blood glucose and hemoglobin A1c using oral aloe vera: a meta-analysis.
        J Alternative Compl Med. 2016 May 6; 22: 450-457https://doi.org/10.1089/acm.2015.0122
        • Innes K.E.
        • Selfe T.K.
        Yoga for adults with type 2 diabetes: a systematic review of controlled trials.
        J Diabetes Res. 2016; 2016: 6979370https://doi.org/10.1155/2016/6979370
      5. Complementary and alternative medicine for diabetes - health Encyclopedia. University of Rochester Medical Center.
        ([Internet] [cited 2021 Mar 9]. Available from:)
        • Wahner-Roedler D.L.
        • Lee M.C.
        • Chon T.Y.
        • Cha S.S.
        • Loehrer L.L.
        • Bauer B.A.
        Physicians' attitudes toward complementary and alternative medicine and their knowledge of specific therapies: 8-Year follow-up at an academic medical center.
        Compl Ther Clin Pract. 2014 Feb 1; 20: 54-60https://doi.org/10.1016/j.ctcp.2013.09.003
      6. Clinical practice guidelines. NCCIH.
        ([Internet] [cited 2021 Mar 9]. Available from:)
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151: 264-269https://doi.org/10.7326/0003-4819-151-4-200908180-00135
        • Brouwers M.C.
        • Kho M.E.
        • Browman G.P.
        • Burgers J.S.
        • Cluzeau F.
        • Feder G.
        • et al.
        AGREE II: advancing guideline development, reporting and evaluation in health care.
        Can Med Assoc J. 2010; 182: E839-E842https://doi.org/10.1503/cmaj.090449
        • Wieland L.S.
        • Manheimer E.
        • Sampson M.
        • Barnabas J.P.
        • Bouter L.M.
        • Cho K.
        • et al.
        Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials.
        Syst Rev. 2013 Jul 4; 2: 51https://doi.org/10.1186/2046-4053-2-51
      7. Operational definition of complementary medicine.
        ([Internet] [cited 2021 Mar 21]. Available from:)
      8. Welcome to G-I-N — guidelines international Network.
        ([Internet] [cited 2021 Mar 20]. Available from:)
      9. Clinical practice guidelines. NCCIH.
        ([Internet] [cited 2021 Mar 20]. Available from:)
        • Matthaei S.
        • Bierwirth R.
        • Fritsche A.
        • Gallwitz B.
        • Häring H.-U.
        • Joost H.-G.
        • et al.
        Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.
        Exp Clin Endocrinol Diabetes. 2009 Oct; 117: 522-557https://doi.org/10.1055/s-0029-1239559
        • Scottish Intercollegiate Guidelines Network
        Management of diabetes: a national clinical guideline.
        Scottish Intercollegiate Guidelines Network, Edinburgh2010 (Available from:)
        • Malaysian Dietitians’ Association
        Medical nutrition therapy guidelines for type 2 diabetes mellitus.
        2013: 1-52 (Available from:)
        • Mallery L.H.
        • Ransom T.
        • Steeves B.
        • Cook B.
        • Dunbar P.
        • Moorhouse P.
        Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the diabetes care program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program.
        J Am Med Dir Assoc. 2013 Nov 1; 14: 801-808https://doi.org/10.1016/j.jamda.2013.08.002
        • Diabetes Australia
        Royal Australian college of general practitioners. General practice management of type 2 diabetes.
        2014
        • International Diabetes Federation Guideline Development Group
        Global guideline for type 2 diabetes.
        Diabetes Res Clin Pract. 2014 Apr; 104: 1-52https://doi.org/10.1016/j.diabres.2012.10.001
        • Handelsman Y.
        • Bloomgarden Z.T.
        • Grunberger G.
        • Umpierrez G.
        • Zimmerman R.S.
        • Bailey T.S.
        • et al.
        American association of clinical endocrinologists and American college of endocrinology – clinical practice guidelines for developing A diabetes mellitus comprehensive care plan – 2015.
        Endocr Pract. 2015 Apr 1; 21: 413-437https://doi.org/10.4158/EP15672.GL
        • HTA DoH (MY) - HTA Unit, Ministry of Health Malaysia
        Management of type 2 diabetes mellitus.
        5th ed. 2015: 1-141 (Available from:)
        • National institute for health and care excellence (NICE)
        Type 2 diabetes in adults: management.
        2015 Dec (Available from:)
        • Aschner P.M.
        • Muñoz O.M.
        • Girón D.
        • García O.M.
        • Fernández-Ávila D.G.
        • Casas L.Á.
        • et al.
        Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
        Colomb Med (Cali). 2016 Jun 30; 47: 109-131
        • Ministry of Public Health Qatar
        The diagnosis and management of type 2 diabetes in adults and the elderly.
        2017
        • Qaseem A.
        • Barry M.J.
        • Humphrey L.L.
        • Forciea M.A.
        Clinical guidelines committee of the American college of physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American college of physicians.
        Ann Intern Med. 2017 Feb 21; 166: 279-290https://doi.org/10.7326/M16-1860
        • Shera A.S.
        • Basit A.
        • Team P.
        Pakistan's recommendations for optimal management of diabetes from Primary to Tertiary care level (PROMPT).
        Pak J Med Sci. 2017 Oct; 33: 1279-1283https://doi.org/10.12669/pjms.335.13665
        • Guidelines 2018
        Can J Diabetes. 2018 Apr; 42: 1-342
        • Silver B.
        • Ramaiya K.
        • Andrew S.B.
        • Fredrick O.
        • Bajaj S.
        • Kalra S.
        • et al.
        EADSG guidelines: insulin therapy in diabetes.
        Diabetes Ther. 2018 Apr; 9: 449-492https://doi.org/10.1007/s13300-018-0384-6
        • Hamdy O.
        • Ganda O.P.
        • Gabbay R.A.
        Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D.
        2016 Oct (Available from:)
        • Munshi M.
        • Blair E.
        • Ganda O.P.
        Guideline for the care of the older adult with diabetes.
        2017 May (Available from:)
        • Bajaj S.
        RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017.
        Int J Diabetes Dev Ctries. 2018 Mar; 38: 1-115https://doi.org/10.1007/s13410-018-0604-7
        • Jia W.
        • Weng J.
        • Zhu D.
        • Ji L.
        • Lu J.
        • Zhou Z.
        • et al.
        Standards of medical care for type 2 diabetes in China 2019.
        Diabetes Metabol Res Rev. 2019; 35: e3158https://doi.org/10.1002/dmrr.3158
        • LeRoith D.
        • Biessels G.J.
        • Braithwaite S.S.
        • Casanueva F.F.
        • Draznin B.
        • Halter J.B.
        • et al.
        Treatment of diabetes in older adults: an endocrine society∗ clinical practice guideline.
        J Clin Endocrinol Metab. 2019 May 1; 104: 1520-1574https://doi.org/10.1210/jc.2019-00198
        • Cosentino F.
        • Grant P.J.
        • Aboyans V.
        • Bailey C.J.
        • Ceriello A.
        • Delgado V.
        • et al.
        2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).
        Eur Heart J. 2020 Jan 7; 41: 255-323https://doi.org/10.1093/eurheartj/ehz486
        • Kim M.K.
        • Ko S.-H.
        • Kim B.-Y.
        • Kang E.S.
        • Noh J.
        • Kim S.-K.
        • et al.
        2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea.
        Diabetes Metab J. 2019 Aug 20; 43: 398-406https://doi.org/10.4093/dmj.2019.0137
        • Araki E.
        • Goto A.
        • Kondo T.
        • Noda M.
        • Noto H.
        • Origasa H.
        • et al.
        Japanese clinical practice guideline for diabetes 2019.
        J Diabet Invest. 2020; 11: 1020-1076https://doi.org/10.1111/jdi.13306
        • Bertoluci M.C.
        • Salles J.E.N.
        • Silva-Nunes J.
        • Pedrosa H.C.
        • Moreira R.O.
        • da Silva Duarte R.M.C.
        • et al.
        Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.
        Diabetol Metab Syndrome. 2020 May 24; 12: 45https://doi.org/10.1186/s13098-020-00551-1
        • Araszkiewicz A.
        • Bandurska-Stankiewicz E.
        • Budzyński A.
        • Cypryk K.
        • Czech A.
        • Czupryniak L.
        • et al.
        2020 Guidelines on the management of diabetic patients.
        Clin Diabetol. 2020; 9: 1-101
        • Joslin Diabetes
        Clinical guideline for pharmacological management of adults with type 2 diabetes.
        2020 Feb (Available from:)
        • Joslin Diabetes
        Clinical guidelines for management of adults with diabetes.
        2020 Feb (Available from:)
        • Anwer M.A.
        • Al-Fahed O.B.
        • Arif S.I.
        • Amer Y.S.
        • Titi M.A.
        • Al-Rukban M.O.
        Quality assessment of recent evidence-based clinical practice guidelines for management of type 2 diabetes mellitus in adults using the AGREE II instrument.
        J Eval Clin Pract. 2018; 24: 166-172https://doi.org/10.1111/jep.12785
        • Ng J.Y.
        • Verma K.D.
        Identifying the quantity and assessing the quality of clinical practice guidelines for the treatment and management of type 2 diabetes: a systematic review.
        Diabetes Res Clin Pract. 2020 Oct 1; 168: 108365https://doi.org/10.1016/j.diabres.2020.108365
        • Bhatt M.
        • Nahari A.
        • Wang P.-W.
        • Kearsley E.
        • Falzone N.
        • Chen S.
        • et al.
        The quality of clinical practice guidelines for management of pediatric type 2 diabetes mellitus: a systematic review using the AGREE II instrument.
        Syst Rev. 2018 Nov 15; 7: 193https://doi.org/10.1186/s13643-018-0843-1
        • Zhang M.
        • Zhou Y.
        • Zhong J.
        • Wang K.
        • Ding Y.
        • Li L.
        • et al.
        Quality appraisal of gestational diabetes mellitus guidelines with AGREE II: a systematic review.
        BMC Pregnancy Childbirth. 2019 Dec 5; 19: 478https://doi.org/10.1186/s12884-019-2597-8
        • Ng J.Y.
        • Mohiuddin U.
        Quality of complementary and alternative medicine recommendations in low back pain guidelines: a systematic review.
        Eur Spine J. 2020 Aug 1; 29: 1833-1844https://doi.org/10.1007/s00586-020-06393-9
        • Ng J.Y.
        • Nazir Z.
        • Nault H.
        Complementary and alternative medicine recommendations for depression: a systematic review and assessment of clinical practice guidelines.
        BMC Compl Med Ther. 2020 Oct 7; 20: 299https://doi.org/10.1186/s12906-020-03085-1
        • Ng J.Y.
        • Kishimoto V.
        Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: a systematic review.
        Compl Ther Med. 2021 Jan 1; 56: 102595https://doi.org/10.1016/j.ctim.2020.102595
        • Ng J.Y.
        • Azizudin A.M.
        Rheumatoid arthritis and osteoarthritis clinical practice guidelines provide few complementary and alternative medicine therapy recommendations: a systematic review.
        Clin Rheumatol. 2020 Oct 1; 39: 2861-2873https://doi.org/10.1007/s10067-020-05054-y
        • Ng J.Y.
        • Sharma A.E.
        Guidelines for cancer-related pain: a systematic review of complementary and alternative medicine recommendations.
        Pain Pract. 2020 Nov 16; (n/a(n/a))https://doi.org/10.1111/papr.12964
        • Ng J.Y.
        • Gilotra K.
        Complementary medicine mention and recommendations are limited across hypertension guidelines: a systematic review.
        Compl Ther Med. 2020 May 1; 50: 102374https://doi.org/10.1016/j.ctim.2020.102374
        • Fischer F.H.
        • Lewith G.
        • Witt C.M.
        • Linde K.
        • von Ammon K.
        • Cardini F.
        • et al.
        High prevalence but limited evidence in complementary and alternative medicine: guidelines for future research.
        BMC Compl Alternative Med. 2014 Feb 6; 14: 46https://doi.org/10.1186/1472-6882-14-46
        • Veziari Y.
        • Leach M.J.
        • Kumar S.
        Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review.
        BMC Compl Alternative Med. 2017 Mar 23; 17: 166https://doi.org/10.1186/s12906-017-1660-0
        • Susilawati D.
        • Sitaresmi M.
        • Handayani K.
        • van de Ven P.
        • null Sutaryo
        • Kaspers G.
        • et al.
        HealthCare providers' and parents' perspectives on complementary alternative medicine in children with cancer in Indonesia.
        Asian Pac J Cancer Prev. 2016; 17: 3235-3242
        • Patel S.J.
        • Kemper K.J.
        • Kitzmiller J.P.
        Physician perspectives on education, training, and implementation of complementary and alternative medicine.
        Adv Med Educ Pract. 2017 Jul 25; 8: 499-503https://doi.org/10.2147/AMEP.S138572